Table 2. Analysis of blood samples after treatment of mice in vivo.
| |
Treatment |
|
|---|---|---|
| Blood values | Vechicle | KPT-330 (10 mg kg−1) |
| WBC ( × 1000 per μl) (range, 2.9–20.9) |
4.6±1.5 |
4.0±0.3 |
| Neut ( × 1000 per μl) (range, 0.15–7.9) |
1.2±0.29 |
1.26±0.5 |
| HCT (%) (range, 34–53) |
34.8±4.9 |
46.2±7.5 |
| PLT ( × 1000 per μl) (range, 685–1436) |
622±82 |
786±180 |
| Alb (g l−1) (range, 25–30) |
34.7±1.5 |
36.5±0.6 |
| ALP (U l−1)(range, 35–96) |
82±22.8 |
96±18 |
| ALT (U l−1) (range, 17–77) |
29±5.2 |
46.2±10.2 |
| CREAT (mg dl−1) (range, 0.2–0.9) | 0.12±0.01 | 0.062±0.01 |
Abbreviations: Alb=albumin; ALP=alkaline phosphatase; ALT=alanine aminotransferase; CREAT=creatinine; HCT=haematocrit; Neut=neutrophils; PLT=platelet; WBC=white blood cell.
Mice were randomly divided into two groups (five mice per group): orally treated with vehicle (0.6% w/v aqueous Pluronic F-68) or KPT-330 (10 mg kg−1, thrice weekly × 4 weekly). Mice were given Nutri-Cal (tomlyn) during therapy to allow robust nutrition. Mean± s.d. of NOD/SCID mice.